PP
GCVRZ

Pegasus Partners’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Pegasus Partners’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Hold
0
– – – 113
2016
Q1 		– Sell
-20,000
Closed -$2.17K – 110
2015
Q4 		$2K Hold
20,000
– – ﹤0.01% 93
2015
Q3 		$4K Hold
20,000
– – ﹤0.01% 88
2015
Q2 		$14K Buy
+20,000
New +$13.8K 0.01% 97

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Pegasus Partners's GCVRZ Position: Q2 2016 in Review

Pegasus Partners held its Sanofi Contingent Value Rights (GCVRZ) position steady in Q2 2016 at 0 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #113.

Pegasus Partners first reported a position in GCVRZ in Q2 2015 and has held it in 3 quarters since. The position peaked at $14K in Q2 2015. 109 funds tracked by Wall St. Rank hold GCVRZ as of Q2 2016.

  • Pegasus Partners held 0 shares of Sanofi Contingent Value Rights worth $5K as of Q2 2016.
  • Pegasus Partners left its Sanofi Contingent Value Rights share count unchanged in Q2 2016.
  • Sanofi Contingent Value Rights made up ﹤0.01% of Pegasus Partners's portfolio in Q2 2016, its #113 holding.
  • Pegasus Partners first reported a position in Sanofi Contingent Value Rights in Q2 2015 and has held it in 3 quarters since.
  • Pegasus Partners's Sanofi Contingent Value Rights position peaked at $14K in Q2 2015.
  • 109 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q2 2016.

Based on Pegasus Partners's 13F filing for Q2 2016, filed 9 Aug 2016.